Biotech's Babies: Doing Well by Doing Good

As Big Pharma pulls out of the low-margin vaccine business, upstart outfits are exploiting new technologies to tap niche markets

By Lisa Miller

To continue reading this article you must be a Bloomberg Professional Service Subscriber.